Hot off the Forge
-
The partnership will help advance Myrtelle’s novel gene therapy for monogenic hearing loss, Myr-201, into clinical trials for patients with…
-
Conferences include upcoming Jefferies, Chardan, and SVB Securities healthcare conferences.
-
New offering complements Forge’s existing AAV process development, analytical development, cGMP manufacturing, and automated final fill capabilities.
-
This round brings the total capital raised to $330 million since Forge’s launch in 2020.
-
Christina Perry, Senior Vice President of Finance & Investor Relations, will be delivering the presentation to investors.
-
Novel approach may lessen many of the immune challenges previously observed with systemic AAV gene delivery.
-
“Forge has grown to over 220 employees and we’re excited to share how we are enabling manufacturing success for our…
-
The board will serve Forge with a distinct and strategic emphasis on manufacturing advancements.
-
Five scientific poster presentations highlight scalable process and analytical developments for AAV manufacturing.
-
Timothy J. Miller, Ph.D., CEO, President, and Co-Founder of Forge Biologics, and David Dismuke, Ph.D., Chief Technical Officer, will be…
-
Forge’s leadership team will be participating at upcoming investor conferences, including Cowen’s and Oppenheimer’s.
-
Partnership will help advance Ray Therapeutics’ lead optogenetics gene therapy program, Ray-001, into clinical trials for patients with retinitis pigmentosa.
ASGCT Breakthroughs in Cell + Gene Therapy
Bringing together professionals in cells and gene therapy to discuss the cutting-edge science and translational advances shaping the future of the field.